Arcutis Biotherapeutics Inc (ARQT)

Apr 24, 2025

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? - MSN

Apr 24, 2025

Apr 20, 2025

Learn to Evaluate (ARQT) using the Charts - news.stocktradersdaily.com

Apr 20, 2025

Apr 19, 2025

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets - Seeking Alpha

Apr 19, 2025

Apr 18, 2025

Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.

Apr 18, 2025

Apr 17, 2025

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 - The Manila Times

Apr 17, 2025

Apr 17, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Is Breakeven Near? - simplywall.st

Apr 17, 2025

Apr 11, 2025

Arcutis Biotherapeutics Appoints New Chief Financial Officer - MSN

Apr 11, 2025

Apr 11, 2025

Arcutis Announces Chief Financial Officer Transition | ARQT Stoc - GuruFocus

Apr 11, 2025

Apr 11, 2025

Arcutis Biotherapeutics (ARQT) Announces CFO Transition - GuruFocus

Apr 11, 2025

Apr 11, 2025

Arcutis Biotherapeutics (ARQT) Announces Transition in CFO Role - GuruFocus

Apr 11, 2025

Apr 11, 2025

Arcutis Names New Chief Financial Officer - Contract Pharma

Apr 11, 2025

Apr 11, 2025

Arcutis CFO David Topper retires, Latha Vairavan steps in By Investing.com - Investing.com India

Apr 11, 2025

Apr 11, 2025

Arcutis Announces Chief Financial Officer Transition - BioSpace

Apr 11, 2025

Apr 10, 2025

Arcutis Biotherapeutics Names New Chief Financial Officer - marketscreener.com

Apr 10, 2025

Apr 10, 2025

Arcutis CFO David Topper retires, Latha Vairavan steps in - Investing.com Australia

Apr 10, 2025

Apr 10, 2025

Psoriasis Pipeline Analysis and Clinical Trials Assessment, - openPR.com

Apr 10, 2025

Apr 08, 2025

Arcutis at Needham Conference: Strategic Growth in Dermatology By Investing.com - Investing.com Canada

Apr 08, 2025

Apr 04, 2025

Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) - Seeking Alpha

Apr 04, 2025

Apr 04, 2025

Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? - MSN

Apr 04, 2025

Apr 04, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 04, 2025

Apr 04, 2025

Arcutis Strengthens Team with Strategic Stock Grants to 5 Key New Hires - Stock Titan

Apr 04, 2025

Apr 04, 2025

(ARQT) Trading Report - news.stocktradersdaily.com

Apr 04, 2025

Apr 03, 2025

Arcutis stock holds buy rating, $19 target amid patent case By Investing.com - Investing.com Australia

Apr 03, 2025

Apr 03, 2025

Arcutis Biotherapeutics director sells $151,236 in stock By Investing.com - Investing.com South Africa

Apr 03, 2025

Apr 03, 2025

Arcutis Biotherapeutics director sells $151,236 in stock - Investing.com India

Apr 03, 2025

Apr 03, 2025

Recent Insider Transactions at Arcutis Biotherapeutics - TradingView

Apr 03, 2025

Apr 03, 2025

Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews - Benzinga

Apr 03, 2025

Apr 03, 2025

Arcutis stock holds buy rating, $19 target amid patent case - Investing.com

Apr 03, 2025

Apr 03, 2025

Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? - Yahoo Finance

Apr 03, 2025

Apr 03, 2025

Arcutis Biotherapeutics (ARQT) Shares Rise Amid Patent Lawsuit P - GuruFocus

Apr 03, 2025

Apr 02, 2025

Arcutis stock rises following litigation stay By Investing.com - Investing.com Canada

Apr 02, 2025

Apr 02, 2025

Arcutis and Padagis agree to stay patent litigation By Investing.com - Investing.com South Africa

Apr 02, 2025

Apr 02, 2025

Arcutis And Padagis Agree To Stay Patent Lawsuit - MarketScreener

Apr 02, 2025

Apr 02, 2025

Arcutis stock gains after pausing patent suit (ARQT:NASDAQ) - Seeking Alpha

Apr 02, 2025

Apr 02, 2025

Arcutis rises after halting patent dispute with Padagis - TradingView

Apr 02, 2025

Apr 02, 2025

Arcutis Agrees to Stay Patent Lawsuit Against Padagis - MarketScreener

Apr 02, 2025

Apr 02, 2025

Arcutis and Padagis Agree to Stay Patent Lawsuit - The Manila Times

Apr 02, 2025

Apr 02, 2025

Arcutis and Padagis agree to stay patent litigation - Investing.com

Apr 02, 2025

Apr 02, 2025

Strategic Win: Arcutis Secures Extended Patent Protection for ZORYVE Until 2037 - Stock Titan

Apr 02, 2025

Apr 02, 2025

Arcutis: An Agent of Patient-Centric Transformation - Technology Magazine

Apr 02, 2025

Mar 31, 2025

Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast - openPR.com

Mar 31, 2025